|
In a year defined by rapid policy changes and shifting market forces, one policy trend is quietly poised to reshape the biotech landscape, Most-Favored-Nation (MFN) Drug Pricing is back, and it’s rewriting the playbook.
Under Executive Order 14297, the U.S. has revived the MFN drug pricing rule, this time with broader reach across Medicare, Medicaid, and Commercial Markets. The new policy's direct-to-patient pricing and global bench-marking provisions represent a paradigm shift in how treatments are priced and covered in the U.S.
For biotech companies, this comes at a moment of strategic re-calibration. As pricing models shift and market dynamics evolve, MFN pricing is encouraging companies to innovate across the development lifecycle from deal terms to trial designs to global launches.
We invite you to join us for an engaging o2h ChaiTime Webinar, where a panel of experts will explore and discuss the potential strategic implications of this shift and open the floor to perspectives on what it could mean for biotech innovators worldwide.
|
